Vnitr Lek 2016, 62(2):114-124

The patient complains of spinal pain or fatigue and weakness. How do I recognize whether their cause is spondylarthrosis, the patient's age or multiple myeloma?

Zdeněk Adam1,*, Eva Pourová2, Luděk Pour1, Eva Michalková1, Marta Krejčí1, Renata Koukalová3, Zdeněk Řehák3, Jiří Vaníček4, Tomáš Nebeský5, Hana Petrášová5, Sabina Ševčíková6, Michal Mašek7, Zdeněk Král1, Aleš Čermák8
1 Interní hematologická a onkologická klinika LF MU a FN Brno
2 Ordinace praktického lékaře pro dospělé Pustiměř
3 Oddělení nukleární medicíny, centrum PET, RECAMO, Masarykův onkologický ústav Brno
4 Klinika zobrazovacích metod LF MU a FN u sv. Anny Brno
5 Radiologická klinika LF MU a FN Brno
6 Katedra patologické fyziologie LF MU Brno
7 Klinika úrazové chirurgie LF MU a FN Brno
8 Urologická klinika LF MU a FN Brno

Multiple myeloma has varied manifestations which resemble common patient complaints and that is why this disease is typically not diagnosed until it reaches an advanced stage. Spinal pains can be an expression of deformative and discogenous changes, but also a symptom of multiple myeloma. Pains in the long bones may result from the pain radiating from an arthrotic joint, but also from a large myelomatic osteolytic lesion which makes the bone prone to a spontaneous fracture. Pathological weariness may have many causes, multiple myeloma being one of them. Anemia may have a large number of causes and multiple myeloma is one of them. Raised creatinine levels and renal failure can also be due to many causes and again, multiple myeloma is one of them. Weakened immunity and frequent infections can also have many causes, among them multiple myeloma. Confusion and sleepiness may be due to psychiatric diagnosis, but also may result from hypercalcemia associated with multiple myeloma. The following text which is designed for non-hematology physicians therefore describes in detail the symptoms of multiple myeloma and diagnostic steps leading to establishing the diagnosis and it only briefly outlines the treatment related information. You can also visit www.myeloma.cz for details. This text aims to summarize the symptoms of multiple myeloma for physicians not specializing in hematology in order to facilitate earlier diagnosing of the disease.

Keywords: monoclonal gammapathy of undetermined significance; multiple myeloma; osteolysis; renal failure

Received: July 31, 2015; Accepted: September 21, 2015; Published: February 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Adam Z, Pourová E, Pour L, Michalková E, Krejčí M, Koukalová R, et al.. The patient complains of spinal pain or fatigue and weakness. How do I recognize whether their cause is spondylarthrosis, the patient's age or multiple myeloma? Vnitr Lek. 2016;62(2):114-124.
Download citation

References

  1. Hájek R, Adam Z, Ščudla V et al. za Českou myelomovou skupinu. Diagnostika a léčba mnohočetného myelomu. Doporučení vypracované Českou myelomovou skupinou. Transfuze a hematologie dnes 2012; 18(Suppl 1). Dostupné z WWW: <http://www.myeloma.cz/res/file/Trans%20suppl%201.pdf>.
  2. Ščudla V, Pika T, Minařík J. Role stanovení těžkých/lehkých párů řetězců imunoglobulinů u monoklonálních gamapatií. Vnitř Lék 2015; 61(1): 60-61; 63-71. Go to PubMed...
  3. Adam Z, Krejčí M, Pour L et al. Monoklonální gamapatie nejistého významu a asymptomatický mnohočetný myelom z pohledu roku 2014. Vnitř Lék 2014; 60(10): 861-879. Go to PubMed...
  4. Špička I, Klánová M. Mnohočetný myelom. Vnitř Lék 2013; 59(7): 627-630. Go to PubMed...
  5. Hrabálek L, Bačovský J, Ščudla V et al. Mnohočetný myelom páteře a jeho chirurgická léčba. Rozhl Chir 2011; 90(5): 270-276. Go to PubMed...
  6. Ščudla V, Herman M, Minařík J et al. Přínos celotělovém magnetické rezonance pro diagnózu MGUS a mnohočetného myelomu a stanovení Durie Salmon staging plus systému. Vnitř Lék 2011; 57(1): 52-60. Go to PubMed...
  7. Vaníček J, Krupa P, Adam Z. Přínos různých zobrazovacích technik pro stanovení diagnózy a sledování aktivity mnohočetného myelomu. Vnitř Lék 2010; 56(6): 585-590. Go to PubMed...
  8. Adam Z, Ščudla V, Krejčí M et al. Léčba AL-amyloidózy, přínos nových léků, bortezomibu, thalidomidu a lenalidomidu. Vnitř Lék 2013; 59(1): 37-58. Go to PubMed...
  9. Adam Z, Štork M, Pour L et al. Výsledky léčby AL-amyloidózy léčebnými režimy obsahujícími bortezomib, dexametazon a dále cyklofosfamid anebo doxorubicin. Vnitř Lék 2012; 58(12): 896-903. Go to PubMed...
  10. Ščudla V, Minařík J, Pika T. Nemoc z ukládání lehkých řetězců imunoglobulinu (light chain deposition disease). Vnitř Lék 2012; 58(1): 38-43. Go to PubMed...
  11. Rajkumar SV, Kyle RA, Baudi FK. Advances in the diagnosis, classification, risk stratification and management of monolocnal gammopathies of undetermined significance: Implication for recategorizing disease entities in the presence of evolving scientific evidence. Mayo Clin Proc 2010; 85(10): 945-948. Go to original source... Go to PubMed...
  12. Mian M, Franz I, Wasle I et al. "Idiopathic Bence-Jones proteinuria": a new characterization of an old entity. Ann Hematol 2013; 92(9): 1263-1270. Go to original source... Go to PubMed...
  13. Fernández de Larrea C, Kyle RA, Durie BG et al. International Myeloma Working Group. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia 2013; 27(4): 780-791. Go to original source... Go to PubMed...
  14. Kyle RA, Durie BG, Rajkumar SV et al. International Myeloma Working Group (IMWG). Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 2010; 24(6): 1121-1127. Go to original source... Go to PubMed...
  15. Hájek R, Plonková H, Gumulec J. Thalidomid v léčbě mnohočetného myelomu se zaměřením na kombinaci s bortezomibem. Klin Onkol. 2013; 26(3): 163-169. Go to original source... Go to PubMed...
  16. Kubiczková L, Matějíková J, Sedlaříková L et al. Proteasomové inhibitory v léčbě mnohočetného myelomu. Klin Onkol 2013; 26(1): 11-18. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.